- Stocks
- Healthcare
- NASDAQ: CYTK

Price (delayed)

$36.3

Market cap

$3.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$3.23B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by

CYTK's equity has surged by 121% year-on-year but it has dropped by 76% since the previous quarter

The EPS has contracted by 9% from the previous quarter but it has grown by 6% YoY

The debt has soared by 73% YoY and by 7% from the previous quarter

Cytokinetics's quick ratio has plunged by 52% from the previous quarter and by 40% YoY

What are the main financial stats of CYTK

Market
Valuations
Earnings

Shares outstanding

83.51M

Market cap

$3.03B

Enterprise value

$3.23B

Price to earnings (P/E)

N/A

Price to book (P/B)

157.93

Price to sales (P/S)

45.06

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

55.93

Revenue

$57.8M

EBIT

-$139.71M

EBITDA

-$137.62M

Free cash flow

-$17.06M

Per share
Balance sheet
Liquidity

EPS

-$2.2

Free cash flow per share

-$0.24

Book value per share

$0.23

Revenue per share

$0.81

TBVPS

$7.86

Total assets

$564.3M

Total liabilities

$547.81M

Debt

$238.51M

Equity

$16.49M

Working capital

$302.46M

Debt to equity

14.46

Current ratio

5.9

Quick ratio

5.72

Net debt/EBITDA

-1.46

Margins
Efficiency
Dividend

EBITDA margin

-238.1%

Gross margin

100%

Net margin

-269.5%

Operating margin

-219.1%

Return on assets

-29%

Return on equity

-179.4%

Return on invested capital

-23.6%

Return on capital employed

-27.8%

Return on sales

-241.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Cytokinetics stock price performed over time

Intraday

-1.97%

1 week

1.48%

1 month

9.57%

1 year

121.48%

YTD

74.69%

QTD

1.57%

How have Cytokinetics's revenue and profit performed over time

Revenue

$57.8M

Gross profit

$57.8M

Operating income

-$126.63M

Net income

-$155.76M

Gross margin

100%

Net margin

-269.5%

The net margin has soared by 64% YoY but it has decreased by 17% from the previous quarter

Cytokinetics's operating margin has soared by 63% YoY but it has decreased by 23% from the previous quarter

Cytokinetics's operating income has decreased by 22% from the previous quarter and by 15% YoY

The net income is down by 15% since the previous quarter and by 11% year-on-year

What is Cytokinetics's growth rate over time

What is Cytokinetics stock price valuation

P/E

N/A

P/B

157.93

P/S

45.06

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

55.93

The EPS has contracted by 9% from the previous quarter but it has grown by 6% YoY

CYTK's equity has surged by 121% year-on-year but it has dropped by 76% since the previous quarter

How efficient is Cytokinetics business performance

The ROS has soared by 65% YoY but it has contracted by 19% from the previous quarter

The company's return on assets has surged by 50% YoY and by 2.4% QoQ

CYTK's return on invested capital is up by 47% year-on-year and by 3.7% since the previous quarter

The return on equity is up by 16% since the previous quarter

What is CYTK's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CYTK.

How did Cytokinetics financials performed over time

The total assets is 3% greater than the total liabilities

The total assets has surged by 143% year-on-year but it has declined by 2.2% since the previous quarter

Cytokinetics's total liabilities has soared by 76% YoY and by 8% from the previous quarter

CYTK's equity has surged by 121% year-on-year but it has dropped by 76% since the previous quarter

The debt has soared by 73% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.